News

23andMe Showcases Breakthroughs in Clinical Immuno-oncology

23andMe Showcases Breakthroughs in Clinical Immuno-oncology

23andMe's Innovative Contributions to Immuno-oncology

23andMe Holding Co. (Nasdaq: ME), a prominent player in human genetics and biopharmaceutical innovation, is poised to share exciting developments regarding its clinical immuno-oncology programs, specifically 23ME-00610 and 23ME-01473, at the esteemed ESMO Congress 2024. This significant event will occur from September 13 to September 17 in Barcelona, showcasing the groundbreaking advancements 23andMe is making in cancer treatment.

Exploring New Clinical Data

The company plans to reveal crucial preliminary findings from the renal cancer and TMB-H/MSI-H cohorts in its Phase 1/2a clinical trial for 23ME-00610, which is a cutting-edge anti-CD200R1 antibody. Additionally, 23andMe will provide insights from analyses that evaluate CD200 as an exploratory tissue-based biomarker associated with the effectiveness of 23ME-00610.

Preclinical Findings and Ongoing Studies

Moreover, 23andMe intends to present preclinical data on 23ME-01473, an anti-ULBP6 monoclonal antibody currently in dose escalation studies that commenced in March 2024. These studies are focused on how 23ME-01473 can effectively target soluble ULBP6, a component that plays a role in creating an immunosuppressive environment within tumors.

Clinical Trial Highlights from ASCO

Delving into its recent trial outcomes, 23andMe showcased promising results at the American Society of Clinical Oncology (ASCO) meeting. The monotherapy with 23ME-00610 demonstrated a favorable safety profile, along with early indications of clinical benefits in cohorts facing advanced cancers. Among the notable outcomes was a confirmed partial response in a patient diagnosed with pancreatic neuroendocrine cancer.

Innovative Biomarker Research

The exploration of CD200 is particularly noteworthy, as findings suggest it could act as a potential tissue-based biomarker, thereby enhancing precision in cancer treatment. This represents a significant advancement toward personalized medicine strategies grounded in genetic and immunological evaluations.

Presentation Details at ESMO

Here are the essential details regarding the presentations scheduled for ESMO:

  • Abstract: 1069TiP
    Title: A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody for Patients with Advanced Solid Malignancies
    Session Type: Poster Session – Investigational Immunotherapy
    Date and Time: September 14, 9:00-17:00 CEST
  • Abstract: 620P
    Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with TMB-H and/or MSI-H Cancers: Results from an Expansion Cohort
    Session Type: Poster Session – Developmental Therapeutics
    Date and Time: September 14, 9:00-17:00 CEST
  • Abstract: 153P
    Title: 23ME-01473 Restores Anti-Tumor NK Cell Function Through NKG2D and FcgRIIIa Activation
    Session Type: Poster Session – Biomarkers and Translational Research
    Date and Time: September 15, 9:00-17:00 CEST
  • Abstract: 1706P
    Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
    Session Type: Poster Session – Renal Cancer
    Date and Time: September 15, 9:00-17:00 CEST
  • Abstract: 150P
    Title: Phase 1/2a Trial of CD200R1 Inhibitor 23ME-00610; Exploratory Analyses of Biomarkers
    Session Type: Poster Session – Biomarkers and Translational Research
    Date and Time: September 15, 9:00-17:00 CEST

Understanding the Innovations

23ME-00610 is engineered to inhibit the interaction between CD200R1 and CD200, targeting the CD200–CD200R1 axis, which is a vital immunological checkpoint that regulates immune tolerance. By targeting this pathway, it may enhance the ability of immune cells to combat cancer more effectively.

In contrast, 23ME-01473 aims to restore anti-tumor immune responses through Natural Killer (NK) and T cells by targeting the ULBP6 ligands that cancer cells often shed to avoid detection. This mechanism bolsters the immune response against tumors, potentially transforming the field of cancer immunotherapy.

About 23andMe

23andMe is leading the way in integrating genetic data into healthcare solutions and developing biopharmaceutical products that promise a healthier future for everyone. They harness genetic insights gathered from millions of participants to investigate and validate potential treatments based on genetic predispositions.

Frequently Asked Questions

What new trials will 23andMe present at ESMO Congress 2024?

23andMe will present trials related to its anti-CD200R1 antibody, 23ME-00610, and the anti-ULBP6 monoclonal antibody, 23ME-01473.

What is 23ME-00610?

23ME-00610 is a first-in-class monoclonal antibody targeting CD200R1, aimed at enhancing immune responses against cancer.

What is the significance of CD200 in cancer treatment?

CD200 serves as an immunological checkpoint; blocking its pathway could restore immune function in cancer patients.

How does 23ME-01473 function?

23ME-01473 targets soluble ULBP6 to encourage NK and T cell recognition of cancer cells, restoring anti-tumor immunity.

What role does 23andMe's genetic database play?

The genetic database enables 23andMe to discover drug targets by correlating genetic variants with immune response and cancer risk.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lyric Health's AI System Promises Data-Driven Revolution

Updated Category News Views 5

A Bold Step in Healthcare Coordination No doubt about it, healthcare is a mess. It's like trying to patch a leaking ship with duct tape—point solutions here, add-ons there, and nothing truly working in harmony. And in storms in Lyric Health, claiming they've got the answer. They've launched an AI-powered Healthcare Operating System meant to unify these disjointed pieces...

Continue Reading
Red Banyan Earns Top Honors in Florida for 2026

Updated Category News Views 6

Red Banyan: A Powerhouse in Reputation Management Boy, have you ever watched a company rise through the ranks almost like a caffeine kick on a drowsy morning? That's Red Banyan for you. This outfit, right out of Fort Lauderdale, snagged the '2026 Best of Florida' award as the cream of the crop in the Business Consulting Firms category. It’s like taking home an Oscar in...

Continue Reading
Goddess Maintenance Co. Eyes BeautyMatter Award

Updated Category News Views 6

Challenging the Haircare Norm with Confidence Goddess Maintenance Co. doesn't just draft a fresh play in the beauty industry playbook—it's ripping out the old pages and setting a new standard. This ain't your granny's haircare game anymore, folks. They're up for a 2026 BeautyMatter Award, a nod to their gut-busting innovation in the conditioner category with their star...

Continue Reading
Finastra Recognized as 2026 Leader in Payment Platforms

Updated Category News Views 7

Finastra Steals the Spotlight in Payments Innovation When it comes to the modern world of finance, nothing screams ‘adapt or fade into oblivion’ like the payments industry. Well, here’s a reality check from QKS Group: Finastra has snatched the spotlight in their SPARK Matrix™ for 2026 as a powerhouse in integrated bank payments platforms. Clearly, this ain’t...

Continue Reading
B2B Growth Hinges on Narrative Coherence, Study Shows

Updated Category News Views 7

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Continue Reading
American Savings Bank IPO Hits NYSE: $129M Raised

Updated Category News Views 13

A Big Day for American Savings Bank Buckled up yet? Because American Savings Bank has just shot onto the NYSE, raising a hefty $129 million. A solid start, I’d say, for a Honolulu-based outfit that now struts around with a valuation tipping beyond $1.03 billion. That’s what you get when you price more than eight million shares at $16 a pop. NYSE:ASBH is the new kid on...

Continue Reading
2026 CEE Awards Highlight Energy Innovation Leaders

Updated Category News Views 7

Showcasing Cutting-Edge Home Energy Innovations It's that time of year again when the brightest innovators in home energy solutions get a nod from the Consortium for Energy Efficiency (CEE). This year's Integrated Home Competition spotlighted five trailblazing products that promise to reshape how we think about energy efficiency, demand flexibility, and sheer user comfort...

Continue Reading
Solar Fencing Revolutionizes North Texas Homes

Updated Category News Views 6

Fences Go Solar: Welcome to the Future Land of fences and sunshine, North Texas is about to see a game changer in home improvement. Southwest Fence & Deck is rolling out the red carpet as an Authorized SOL Fence Installation Partner, putting solar power right in your backyard. Yeah, there have been sparks of innovation in plenty of fields, but who expected fences to join...

Continue Reading
Ransoms and Mega-Losses Surge in Cyber Claims Study

Updated Category News Views 5

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Continue Reading
Propensity Rockets to No. 70 on the 2026 Inc. 5000 List

Updated Category News Views 6

Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...

Continue Reading

Top 5 Most Recently Viewed Articles

HealthCentral Celebrates Fourth Consecutive MM&M Award Win

Updated Category News Views 190

HealthCentral Takes Center Stage at MM&M Awards HealthCentral, a prominent digital health platform catering to individuals with chronic illnesses, has been honored with the prestigious Gold Award by Medical Marketing & Media (MM&M). This accolade marks a significant achievement for the brand, as it has won this recognition for four consecutive years. Innovative Approach...

Continue Reading
Synchrony Financial to Reveal Insights for Q3 Performance

Updated Category News Views 69

Synchrony Financial to Announce Q3 Results Synchrony, a prominent player in consumer financial services, is preparing to release its third-quarter financial results for 2024. These results are slated for a Wednesday in mid-October. This announcement holds significant importance for investors and analysts who actively track Synchrony's standing within the financial sector....

Continue Reading
Dan Schwartz's New Role at NABH Boosts Quality Services

Updated Category News Views 294

Dan Schwartz Appointed as Director of Quality and Addiction Services The National Association for Behavioral Healthcare (NABH) is thrilled to announce the appointment of Dan Schwartz as the association's Director of Quality and Addiction Services. With a robust background in federal agencies and a focus on addiction services, Dan steps into this pivotal role to foster...

Continue Reading
Key Stock Market Movers: Successes from APLD to ORBS

Updated Category News Views 231

Positive Trends in the Stock Market On a notable trading day, U.S. stocks showed an uplifting trend, with the Dow Jones index registering a gain of around 150 points. This upwards momentum indicates a positive shift in the market, encouraging investors and analysts alike. Elastic N.V. Celebrates Major Dealings Exciting Developments Shares of Elastic N.V. (NYSE: ESTC)...

Continue Reading
Chegg Shares Decline as Earnings Miss Expectations

Updated Category News Views 160

Chegg Sees Stock Drop Following Earnings Report Chegg, Inc. CHGG has recently seen a notable decline in its stock prices following the announcement of its earnings for the fourth quarter of the 2024 fiscal year. The report revealed that the company's expectations for future revenues fell short of analyst predictions, leading to an unsettling reaction from the market. What...

Continue Reading